Logo

Xbrane to Initiate New Biosimilar Development Program Annually

Share this
Xbrane to Initiate New Biosimilar Development Program Annually

Xbrane to Initiate New Biosimilar Development Program Annually

Shots:

  • Xbrane to initiate a new biosimilar development program annually and planning to generate positive operating cash flow monthly on the back of expected Xlucane net-income by late 2023/early 2024
  • Xlucane (biosimilar- ranibizumab) referencing Lucentis is currently in the P-III trial with expected results in mid-2021- regulatory submissions are underway in the EU in Q3 & the US in Q4’21. If approved- Xlucane will be launched across the EU and the US
  • The company has set the foundation for growth through establishing a new biotech lab at Campus Solna with a team of 50 professionals to take biosimilars from cell-line to approval and strengthen its high yield/low-cost platform technology

Ref: Xbrane | Image: Xbrane

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions